Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$12.22B
Positions
121
New
7
Increased
22
Decreased
10
Sold Out
20
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $12.22B across 121 positions in their Q1 2017 SEC 13F filing (period ending 2017-03-31). The top 10 positions account for 86.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $4.56B | 37.31% | +45.2% |
| 2 | SGENEURSeattle Genetics, Inc. | $2.87B | 23.51% | +0.0% |
| 3 | ACADACADIA Pharmaceuticals Inc. | $887.68M | 7.26% | - |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $793.41M | 6.49% | +0.0% |
| 5 | GHDXGenomic Health, Inc. | $433.65M | 3.55% | +0.0% |
| 6 | BMRNBioMarin Pharmaceutical Inc. | $421.91M | 3.45% | - |
| 7 | DBV Technologies S.A. | $194.05M | 1.59% | - |
| 8 | Aquinox Pharmaceuticals, Inc. | $182.49M | 1.49% | +3.8% |
| 9 | ONCBeiGene, Ltd. | $134.47M | 1.10% | - |
| 10 | AKAOQAchaogen, Inc. | $115.61M | 0.95% | - |
| Stock | Value | Shares |
|---|---|---|
| NVAX 3.75 02/01/23Novavax, Inc. | $48.55M | 108,500,000 |
| ANABAnaptysBio, Inc. | $4.16M | 150,000 |
| JNCEEURJounce Therapeutics, Inc. | $2.20M | 100,000 |
| Tonix Pharmaceuticals Holdings Corp. | $2.10M | 449,500 |
| Bioverativ Inc. | $449.00K | 8,249 |
| ATIBioverativ Inc. | $449.00K | 8,249 |
| BioPharmX Corporation | $191.00K | 377,295 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.